Thymalin

Thymalin is a polypeptide complex extracted from calf thymus glands, not a single defined peptide. Its primary active component has been identified as the dipeptide Glu-Trp (glutamyl-tryptophan, molecular weight 333.34 Da, marketed separately as Thymogen), though the full extract contains multiple bioactive polypeptides in the 1,000–10,000 Da range that may contribute to its effects. Thymalin is the foundational compound in Vladimir Khavinson's peptide bioregulation paradigm — the concept that short, tissue-specific peptides can modulate gene expression and restore age-related functional decline in their target organs.

The proposed mechanism — distinct from conventional receptor-mediated pharmacology — involves direct peptide-DNA interaction: the dipeptide Glu-Trp has been shown to bind specific DNA sequences in the promoter regions of genes involved in immune function, potentially modulating chromatin structure and altering the accessibility of these genes for transcription. In cell culture, Thymalin peptides upregulate expression of interleukin-2 (IL-2), IL-7, interferon-gamma, and T-cell receptor components while downregulating excessive inflammatory cytokine production. This gene-level mechanism explains the temporal dissociation between the short plasma half-life (~30 minutes) and the prolonged biological effects (24–72 hours) — once gene expression patterns are reset, the cellular machinery continues operating in the new transcriptional state long after the peptide itself is cleared.

At the cellular level, Thymalin promotes T-lymphocyte maturation and differentiation in the thymus, normalizes CD4/CD8 (helper/suppressor) T-cell ratios, enhances phagocytic activity of neutrophils and macrophages, and modulates the balance between pro-inflammatory (TNF-α, IL-6) and anti-inflammatory cytokines. It also influences the neuroendocrine-immune axis — modulating melatonin secretion, cortisol rhythms, and hypothalamic-pituitary function. The peptide's effects are most pronounced in immunocompromised states, suggesting it restores impaired function rather than overstimulating a normal immune system — a hallmark of true immunomodulation rather than simple immune stimulation.

Thymalin was developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov at the Military Medical Academy in Saint Petersburg, Russia, emerging from a research program that asked whether age-related organ decline could be slowed by supplementing the peptide signals those organs naturally produce. The thymus gland — which undergoes progressive involution beginning in puberty and is largely replaced by fat by age 50 — was identified as a critical target for immune aging.

Registered as an immunomodulatory medication in the Soviet Union in 1982, Thymalin became one of the first peptide bioregulators to receive formal pharmaceutical registration. Long-term clinical studies by Khavinson reported restoration of immune function in elderly patients and potential lifespan extension. A landmark geroprotective study (Khavinson & Morozov, 2001–2003) documented that elderly subjects receiving Thymalin + Epithalon bi-annual courses over 12 years showed reduced all-cause mortality and lower rates of age-associated disease compared to controls. However, as with most Khavinson bioregulators, the evidence base is predominantly Russian-language literature, and independent Western replication remains limited as of 2026.

Thymalin is typically supplied as a lyophilized powder for injection (white to off-white). Store lyophilized vials at 2–8°C, protected from light. Unlike many synthetic peptides that require -20°C storage, Thymalin's Russian Pharmacopoeia specifications call for refrigerated (not frozen) storage, likely reflecting its nature as a polypeptide extract rather than a single synthetic peptide.

After reconstitution, Thymalin has a notably short in-solution stability window: use within 24 hours when stored at 2–8°C. This is significantly shorter than most research peptides and reflects the complex polypeptide mixture's susceptibility to degradation. Do not freeze reconstituted solutions. For this reason, Thymalin is typically researched as a short, intensive 5–10 day course rather than ongoing daily administration — the protocol naturally aligns with the stability limitations. Discard any unused reconstituted solution after 24 hours.